RePo4EU Live: Enabling Collaborative Drug Repurposing Through Guided Use Cases

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d12829484e97">One of REPO4EU’s key objectives is to build a sustainable, user-centric, industry-level platform certified to ISO 15408, supporting collaborative and translational drug repurposing across disciplines and all relevant stakeholders. To reduce the risk and – from a patient’s benefit perspective – increase the precision of drug repurposing, a systems medicine suite of software and workflows is included along with ethics-by-design, predictive pre-clinical model suggestions, tools for clinical trial design and guidance for intellectual property protection and business development strategies. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e99">All services are to be free, except a members-only section for use of those features and databases that are not open access and incur use-dependent costs. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e101">Listening to international stakeholders and carefully refining their requirements, we shape their input into clear workflows and designs, building the platform step by step. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e103">Here, we present the first alpha version examples of how the platform facilitates real-world decision-making through guided, interactive use cases that investigate “choke points” along the development path. This is achieved through structured navigation, decision-support trees, and curated, up-to-date knowledge tailored to the diverse needs of drug repurposing stakeholders, as well as recommendations from RePo4EU. Through a series of practical scenarios, we show how users can engage with the platform to identify suitable trial designs or navigate early discovery challenges—backed by expert-curated content and interoperable resources. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e105">A key innovation beyond the original plan is an AI layer, enabled by recent breakthroughs in large-language models, that permeates the platform by design and acts as a robust backbone, ensuring dynamic personalization across all modules and offering context-aware guidance, intelligent matchmaking, and decision support. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e107">By connecting with ScienceOpen’s Drug Repurposing Central, the platform provides a one-stop access to all relevant research and industry knowledge. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e109">Training modules are collaborative and user-driven, covering both platform use and drug repurposing topics, and are continuously refined through feedback and updated as necessary. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d12829484e111">With the 2026 beta and 2027 first full release version, the RePo4EU platform will become a living ecosystem that supports reproducibility, transparency, and cross-disciplinary alignment in drug repurposing.